Browsing publications by Professor John Lunec

Newcastle AuthorsTitleYearFull text
Dr Catherine Drummond
Arman Esfandiari
Dr Xiaohong Lu
Dr Claire Hutton
Dr Jennifer Jackson
et al.
TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation2016
Arman Esfandiari
Dr Sirintra Nakjang
Professor John Lunec
Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner2016
Dr Ioannis Kotsopoulos
Ali Kucukmetin
Dr Asima Mukhopadhyay
Professor John Lunec
Professor Nicola Curtin
et al.
Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis Mechanism and Potential Role for PARP Inhibitors2016
Maryam Zanjirband Zanjirband
Professor Richard Edmondson
Professor John Lunec
Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents in combined treatment with cisplatin in ovarian cancer2016
Dr Jeffry Hogg
Professor Derek Manas
Dr Daniela Lee
Dr Petra Dildey
Professor John Lunec
et al.
Surgical outcome and patterns of recurrence for retroperitoneal sarcoma at a single centre.2016
Dr Laura Woodhouse
Clark Crawford
Dr Scott Marshall
Dr Nicholas Bown
Dr Elaine Willmore
et al.
Assessment and targeting of the MDM2-p53 network in CLL2015
Dr Arman Esfandiari
Professor Nicola Curtin
Professor John Lunec
Chemical inhibition or transient knockdown of wild-type p53 induced phosphatase 1 (WIP1/PPM1D) potentiates the response to MDM2 inhibitors in a p53-dependent manner2015
Dr Nicholas Bown
Professor John Lunec
Professor Deborah Tweddle
Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification2015
Dr Ashleigh Herriott
Dr Susan Tudhope
Gesa Junge
Natalie Rodrigues
Dr Miranda Patterson
et al.
PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in Chronic Lymphocytic Leukaemia2015
Professor Ruth Plummer
Dr Jane Margetts
Professor John Lunec
Dr Joyce Nutt
Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker2015
12345678910111213141516171819